Search

Your search keyword '"Angermann, Christiane E."' showing total 584 results
Start Over Author "Angermann, Christiane E."
584 results on '"Angermann, Christiane E."'

4. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study

Author

Gerhardt, Teresa, Gerhardt, Louisa M S, Ouwerkerk, Wouter, Roth, Gregory A, Dickstein, Kenneth, Collins, Sean P, Cleland, John G F, Dahlstrom, Ulf, Tay, Wan Ting, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Filippatos, Gerasimos, Lam, Carolyn S P, Tromp, Jasper, and Angermann, Christiane E

Published
2023
Full Text
View/download PDF

5. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry

Author

Tromp, Jasper, Ezekowitz, Justin A., Ouwerkerk, Wouter, Chandramouli, Chanchal, Yiu, Kai Hang, Angermann, Christiane E., Dahlstrom, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V., Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Dickstein, Kenneth, Collins, Sean P., Filippatos, Gerasimos, Cleland, John G.F., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

8. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Author

Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, and Ponikowski, Piotr

Published
2022
Full Text
View/download PDF

9. Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF-NETs) und Herzinsuffizienz-Einheiten (Heart Failure Units [HFUs]) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz – Update 2021: Gemeinsame Empfehlungen der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK) und der Deutschen Gesellschaft für Thorax‑, Herz- und Gefäßchirurgie (DGTHG), herausgegeben vom Vorstand der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. gemeinsam mit der DGTHG, der ALKK und dem BNK

Author

Pauschinger, Matthias, Störk, Stefan, Angermann, Christiane E., Bauersachs, Johann, Bekeredjian, Raffi, Beyersdorf, Friedhelm, Böhm, Michael, Frey, Norbert, Gummert, Jan, Kindermann, Ingrid, Perings, Stefan, Schulze, P. Christian, von Scheidt, Wolfgang, and Raake, Philip

Published
2022
Full Text
View/download PDF

12. Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE.

Author

Ferreira, João Pedro, Blatchford, Jonathan P., Teerlink, John R., Kosiborod, Mikhail N., Angermann, Christiane E., Biegus, Jan, Collins, Sean P., Tromp, Jasper, Nassif, Michael E., Psotka, Mitchell A., Comin‐Colet, Josep, Mentz, Robert J., Brueckmann, Martina, Nordaby, Matias, Ponikowski, Piotr, and Voors, Adriaan A.

Subjects
FAILURE analysis, DRUG efficacy, CARDIOVASCULAR disease related mortality, HOSPITAL admission & discharge, PEPTIDES, HEART failure
Abstract

Aims: Patients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days after hospital admission. The timing of treatment initiation may influence the efficacy and safety of drugs such as empagliflozin. The aim of this study was to evaluate patient characteristics, clinical events, and treatment effects according to time from admission to randomization. Methods and results: The EMPULSE population was dichotomized by median time from hospital admission to randomization (1–2 days vs. 3–5 days). The primary outcome was a hierarchical composite endpoint of time to all‐cause death, number of HF events, time to first HF event, and a ≥5‐point difference in Kansas City Cardiomyopathy Questionnaire total symptom score change from baseline after 90 days, analysed using the win ratio (WR) method. Patients randomized later (3–5 days, average time 3.9 days; n = 312) had a higher risk of experiencing clinical events than patients randomized earlier (1–2 days, average time 1.7 days; n = 215). The treatment effect favoured empagliflozin versus placebo in patients randomized later (3–5 days: WR 1.69, 95% confidence interval [CI] 1.26–2.25) but was attenuated in patients randomized earlier (1–2 days: WR 1.04, 95% CI 0.74–1.44) (interaction p = 0.029). A similar pattern was observed for the composite of HF hospitalization or cardiovascular death and all‐cause hospitalizations (interaction p < 0.1 for both). The reduction of N‐terminal pro‐B‐type natriuretic peptide levels was more pronounced with empagliflozin among patients randomized later than in patients randomized earlier (interaction p = 0.004). Conclusions: Among patients hospitalized for acute HF enrolled in EMPULSE, those randomized later after hospital admission (3–5 days) experienced greater clinical benefit with empagliflozin than those randomized earlier (1–2 days). These findings should be confirmed in future studies before clinical application. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study

Author

Tromp, Jasper, Bamadhaj, Sahiddah, Cleland, John G F, Angermann, Christiane E, Dahlstrom, Ulf, Ouwerkerk, Wouter, Tay, Wan Ting, Dickstein, Kenneth, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Lam, Carolyn S P, Filippatos, Gerasimos, and Collins, Sean P

Published
2020
Full Text
View/download PDF

19. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial.

Author

Tromp, Jasper, Kosiborod, Mikhail N., Angermann, Christiane E., Collins, Sean P., Teerlink, John R., Ponikowski, Piotr, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Brueckmann, Martina, Blatchford, Jonathan P, Steubl, Dominik, and Voors, Adriaan A.

Subjects
HEART failure, HEART failure patients, VENTRICULAR ejection fraction, SODIUM-glucose cotransporter 2 inhibitors, EMPAGLIFLOZIN, TREATMENT effectiveness
Abstract

Aim: The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium–glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF). We investigated whether efficacy and safety of empagliflozin were consistent across the spectrum of left ventricular ejection fraction (LVEF). Methods and results: A total of 530 patients hospitalized for acute de novo or decompensated HF were included irrespective of LVEF. For the present analysis, patients were classified as HF with reduced (HFrEF, LVEF ≤40%), mildly reduced (HFmrEF, LVEF 41–49%) or preserved (HFpEF, LVEF ≥50%) ejection fraction at baseline. The primary endpoint was a hierarchical outcome of death, worsening HF events (HFE) and quality of life over 90 days, assessed by the win ratio. Secondary endpoints included individual components of the primary endpoint and safety. Out of 523 patients with baseline data, 354 (67.7%) had HFrEF, 54 (10.3%) had HFmrEF and 115 (22.0%) had HFpEF. The clinical benefit (hierarchical composite of all‐cause death, HFE and Kansas City Cardiomyopathy Questionnaire total symptom score) of empagliflozin at 90 days compared to placebo was consistent across LVEF categories (≤40%: win ratio 1.35 [95% confidence interval 1.04, 1.75]; 41–49%: win ratio 1.25 [0.66, 2.37)] and ≥50%: win ratio 1.40 [0.87, 2.23], pinteraction = 0.96) with a favourable safety profile. Results were consistent across individual components of the hierarchical primary endpoint. Conclusion: The clinical benefit of empagliflozin proved consistent across LVEF categories in the EMPULSE trial. These results support early in‐hospital initiation of empagliflozin regardless of LVEF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Prevalence of anti‐beta‐1 antibody 6 months after hospitalization for acute heart failure predicts adverse outcome

Author

Morbach, Caroline, primary, Beyersdorf, Niklas, additional, Moser, Nicola, additional, Pelin, Dora, additional, Afshar, Boshra, additional, Ramos, Gustavo, additional, Kerkau, Thomas, additional, Kaiser, Elisa, additional, Lamers, Janna, additional, Pätkau, Jannika, additional, Sahiti, Floran, additional, Albert, Judith, additional, Güder, Gülmisal, additional, Ertl, Georg, additional, Angermann, Christiane E., additional, Frantz, Stefan, additional, Hofmann, Ulrich, additional, Jahns, Roland, additional, Jahns, Valerie, additional, and Störk, Stefan, additional

Published
2023
Full Text
View/download PDF

24. Hospitalization for acute heart failure during non‐working hours impacts on long‐term mortality: the REPORT‐HF registry

Author

Katsanos, Spyridon, primary, Ouwerkerk, Wouter, additional, Farmakis, Dimitrios, additional, Collins, Sean P., additional, Angermann, Christiane E., additional, Dickstein, Kenneth, additional, Tomp, Jasper, additional, Ertl, Georg, additional, Cleland, John, additional, Dahlström, Ulf, additional, Obergfell, Achim, additional, Ghadanfar, Mathieu, additional, Perrone, Sergio V., additional, Hassanein, Mahmoud, additional, Stamoulis, Konstantinos, additional, Parissis, John, additional, Lam, Carolyn, additional, and Filippatos, Gerasimos, additional

Published
2023
Full Text
View/download PDF

25. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE

Author

Ferreira, João Pedro, primary, Blatchford, Jonathan P., additional, Teerlink, John R., additional, Kosiborod, Mikhail N., additional, Angermann, Christiane E., additional, Biegus, Jan, additional, Collins, Sean P., additional, Tromp, Jasper, additional, Nassif, Michael E., additional, Psotka, Mitchell A., additional, Comin‐Colet, Josep, additional, Mentz, Robert J., additional, Brueckmann, Martina, additional, Nordaby, Matias, additional, Ponikowski, Piotr, additional, and Voors, Adriaan A., additional

Published
2023
Full Text
View/download PDF

32. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT‐HF

Author

Farmakis, Dimitrios, primary, Tromp, Jasper, additional, Marinaki, Smaragdi, additional, Ouwerkerk, Wouter, additional, Angermann, Christiane E., additional, Bistola, Vasiliki, additional, Dahlstrom, Ulf, additional, Dickstein, Kenneth, additional, Ertl, Georg, additional, Ghadanfar, Mathieu, additional, Hassanein, Mahmoud, additional, Obergfell, Achim, additional, Perrone, Sergio V., additional, Polyzogopoulou, Eftihia, additional, Schweizer, Anja, additional, Boletis, Ioannis, additional, Cleland, John G.F., additional, Collins, Sean P., additional, Lam, Carolyn S.P., additional, and Filippatos, Gerasimos, additional

Published
2023
Full Text
View/download PDF

33. The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse

Author

Pocock, Stuart J., primary, Ferreira, João Pedro, additional, Collier, Timothy J., additional, Angermann, Christiane E., additional, Biegus, Jan, additional, Collins, Sean P., additional, Kosiborod, Mikhail, additional, Nassif, Michael E., additional, Ponikowski, Piotr, additional, Psotka, Mitchell A., additional, Teerlink, John R., additional, Tromp, Jasper, additional, Gregson, John, additional, Blatchford, Jonathan P., additional, Zeller, Cordula, additional, and Voors, Adriaan A., additional

Published
2023
Full Text
View/download PDF

34. Hospitalization for acute heart failure during non-working hours impacts on long-term mortality: the REPORT-HF registry

Author

Katsanos, Spyridon, Ouwerkerk, Wouter, Farmakis, Dimitrios, Collins, Sean P., Angermann, Christiane E., Dickstein, Kenneth, Tomp, Jasper, Ertl, Georg, Cleland, John, Dahlström, Ulf, Obergfell, Achim, Ghadanfar, Mathieu, Perrone, Sergio V., Hassanein, Mahmoud, Stamoulis, Konstantinos, Parissis, John, Lam, Carolyn, Filippatos, Gerasimos, Katsanos, Spyridon, Ouwerkerk, Wouter, Farmakis, Dimitrios, Collins, Sean P., Angermann, Christiane E., Dickstein, Kenneth, Tomp, Jasper, Ertl, Georg, Cleland, John, Dahlström, Ulf, Obergfell, Achim, Ghadanfar, Mathieu, Perrone, Sergio V., Hassanein, Mahmoud, Stamoulis, Konstantinos, Parissis, John, Lam, Carolyn, and Filippatos, Gerasimos

Abstract

Aims Hospital admission during nighttime and off hours may affect the outcome of patients with various cardiovascular conditions due to suboptimal resources and personnel availability, but data for acute heart failure remain controversial. Therefore, we studied outcomes of acute heart failure patients according to their time of admission from the global International Registry to assess medical practice with lOngitudinal obseRvation for Treatment of Heart Failure.Methods and results Overall, 18 553 acute heart failure patients were divided according to time of admission into morning (7:00-14:59), evening (15:00-22:59), and night (23:00-06:59) shift groups. Patients were also dichotomized to admission during working hours (9:00-16:59 during standard working days) and non-working hours (any other time). Clinical characteristics, treatments, and outcomes were compared across groups. The hospital length of stay was longer for morning (odds ratio: 1.08; 95% confidence interval: 1.06-1.10, P < 0.001) and evening shift (odds ratio: 1.10; 95% confidence interval: 1.07-1.12, P < 0.001) as compared with night shift. The length of stay was also longer for working vs. non-working hours (odds ratio: 1.03; 95% confidence interval: 1.02-1.05, P < 0.001). There were no significant differences in in-hospital mortality among the groups. Admission during working hours, compared with non-working hours, was associated with significantly lower mortality at 1 year (hazard ratio: 0.88; 95% confidence interval: 0.80-0.96, P = 0.003).Conclusions Acute heart failure patients admitted during the night shift and non-working hours had shorter length of stay but similar in-hospital mortality. However, patients admitted during non-working hours were at a higher risk for 1 year mortality. These findings may have implications for the health policies and heart failure trials., Funding Agencies|Novartis

Published
2023
Full Text
View/download PDF

35. Association of time-to-intravenous furosemide with mortality in acute heart failure : data from REPORT-HF

Author

Ouwerkerk, Wouter, Tromp, Jasper, Cleland, John G. F., Angermann, Christiane E., Dahlström, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Dickstein, Kenneth, Filippatos, Gerasimos, Collins, Sean P., Lam, Carolyn S. P., Ouwerkerk, Wouter, Tromp, Jasper, Cleland, John G. F., Angermann, Christiane E., Dahlström, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Dickstein, Kenneth, Filippatos, Gerasimos, Collins, Sean P., and Lam, Carolyn S. P.

Abstract

AimAcute heart failure can be a life-threatening medical condition. Delaying administration of intravenous furosemide (time-to-diuretics) has been postulated to increase mortality, but prior reports have been inconclusive. We aimed to evaluate the association between time-to-diuretics and mortality in the international REPORT-HF registry.Methods and resultsWe assessed the association of time-to-diuretics within the first 24 h with in-hospital and 30-day post-discharge mortality in 15 078 patients from seven world regions in the REPORT-HF registry. We further tested for effect modification by baseline mortality risk (ADHERE risk score), left ventricular ejection fraction (LVEF) and region. The median time-to-diuretics was 67 (25th-75th percentiles 17-190) min. Women, patients with more signs and symptoms of heart failure, and patients from Eastern Europe or Southeast Asia had shorter time-to-diuretics. There was no significant association between time-to-diuretics and in-hospital mortality (p > 0.1). The 30-day mortality risk increased linearly with longer time-to-diuretics (administered between hospital arrival and 8 h post-hospital arrival) (p = 0.016). This increase was more significant in patients with a higher ADHERE risk score (p(interaction) = 0.008), and not modified by LVEF or geographic region (p(interaction) > 0.1 for both).ConclusionIn REPORT-HF, longer time-to-diuretics was not associated with higher in-hospital mortality. However, we did found an association with increased 30-day mortality, particularly in high-risk patients, and irrespective of LVEF or geographic region.Clinical Trial Registration: ClinicalTrials.gov Identifier NCT02595814., Funding Agencies|National University of Singapore; Singapore Ministry of Education; CS-IRG New Investigator Grant from the National Medical Research; Novartis

Published
2023
Full Text
View/download PDF

36. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF

Author

Farmakis, Dimitrios, Tromp, Jasper, Marinaki, Smaragdi, Ouwerkerk, Wouter, Angermann, Christiane E. E., Bistola, Vasiliki, Dahlström, Ulf, Dickstein, Kenneth, Ertl, Georg, Ghadanfar, Mathieu, Hassanein, Mahmoud, Obergfell, Achim, Perrone, Sergio V. V., Polyzogopoulou, Eftihia, Schweizer, Anja, Boletis, Ioannis, Cleland, John G. F., Collins, Sean P. P., Lam, Carolyn S. P., Filippatos, Gerasimos, Farmakis, Dimitrios, Tromp, Jasper, Marinaki, Smaragdi, Ouwerkerk, Wouter, Angermann, Christiane E. E., Bistola, Vasiliki, Dahlström, Ulf, Dickstein, Kenneth, Ertl, Georg, Ghadanfar, Mathieu, Hassanein, Mahmoud, Obergfell, Achim, Perrone, Sergio V. V., Polyzogopoulou, Eftihia, Schweizer, Anja, Boletis, Ioannis, Cleland, John G. F., Collins, Sean P. P., Lam, Carolyn S. P., and Filippatos, Gerasimos

Abstract

Aim Evidence on healthcare resource utilization (HCRU) for hospitalized patients with heart failure (HF) and reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) ejection fraction is limited.Methods and results We analysed HCRU in relation to left ventricular ejection fraction (LVEF) phenotypes, clinical features and in-hospital and 12-month outcomes in 16 943 patients hospitalized for HF in a worldwide registry. HFrEF was more prevalent (53%) than HFmrEF (17%) or HFpEF (30%). Patients with HFmrEF and HFpEF were older, more often women, with milder symptoms and more comorbidities, but differences were not pronounced. HCRU was high in all three groups; two or more in- and out-of-hospital services were required by 51%, 49% and 52% of patients with HFrEF, HFmrEF and HFpEF, respectively, and intensive care unit by 41%, 41% and 37%, respectively. Hospitalization length was similar (median, 8 days). Discharge prescription of neurohormonal inhibitors was <80% for each agent in HFrEF and only slightly lower in HFmrEF and HFpEF (74% and 67%, respectively, for beta-blockers). Compared to HFrEF, 12-month all-cause and cardiovascular mortality were lower for HFmrEF (adjusted hazard ratios 0.78 [95% confidence interval 0.59-0.71] and 0.80 [0.70-0.92]) and HFpEF (0.64 [0.59-0.87] and 0.63 [0.56-0.71]); 12-month HF hospitalization was also lower for HFpEF and HFmrEF (21% and 20% vs. 25% for HFrEF). In-hospital mortality, 12-month non-cardiovascular mortality and 12-month all-cause hospitalization were similar among groups.Conclusions In patients hospitalized for HF, overall HCRU was similarly high across LVEF spectrum, reflecting the subtle clinical differences among LVEF phenotypes during hospitalization. Discharge prescription of neurohormonal inhibitors was suboptimal in HFrEF and lower but significant in patients with HFpEF and HFmrEF, who had better long-term cardiovascular outcomes than HFrEF, but similar risk for non-cardiovascular events., Funding Agencies|Novartis Pharma AG

Published
2023
Full Text
View/download PDF

38. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of <scp>REPORT‐HF</scp>

Author

Farmakis, Dimitrios, Tromp, Jasper, Marinaki, Smaragdi, Ouwerkerk, Wouter, Angermann, Christiane E, Bistola, Vasiliki, Dahlstrom, Ulf, Dickstein, Kenneth, Ertl, Georg, Ghadanfar, Mathieu, Hassanein, Mahmoud, Obergfell, Achim, Perrone, Sergio V, Polyzogopoulou, Eftihia, Schweizer, Anja, Boletis, Ioannis, Cleland, John Gf, Collins, Sean P, Lam, Carolyn Sp, FIlippatos, Gerasimos, Epidemiology and Data Science, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, and AII - Cancer immunology

Subjects
Left ventricular ejection fraction, Heart failure, Mortality, Heart failure hospitalization, Prognosis, Cardiology and Cardiovascular Medicine, Pharmacotherapy
Abstract

Aim: Evidence on healthcare resource utilization (HCRU) for hospitalized patients with heart failure (HF) and reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) ejection fraction is limited. Methods and results: We analysed HCRU in relation to left ventricular ejection fraction (LVEF) phenotypes, clinical features and in-hospital and 12-month outcomes in 16 943 patients hospitalized for HF in a worldwide registry. HFrEF was more prevalent (53%) than HFmrEF (17%) or HFpEF (30%). Patients with HFmrEF and HFpEF were older, more often women, with milder symptoms and more comorbidities, but differences were not pronounced. HCRU was high in all three groups; two or more in- and out-of-hospital services were required by 51%, 49% and 52% of patients with HFrEF, HFmrEF and HFpEF, respectively, and intensive care unit by 41%, 41% and 37%, respectively. Hospitalization length was similar (median, 8 days). Discharge prescription of neurohormonal inhibitors was

Published
2023
Full Text
View/download PDF

41. Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study

Author

Morbach, Caroline, Buck, Thomas, Rost, Christian, Peter, Sebastian, Günther, Stephan, Störk, Stefan, Prettin, Christiane, Erbel, Raimund, Ertl, Georg, Angermann, Christiane E., and On Behalf of the Handheld-BNP Research Network

Published
2017
Full Text
View/download PDF

43. Association of time‐to‐intravenous furosemide with mortality in acute heart failure: data from REPORT‐HF

Author

Ouwerkerk, Wouter, primary, Tromp, Jasper, additional, Cleland, John G.F., additional, Angermann, Christiane E., additional, Dahlstrom, Ulf, additional, Ertl, Georg, additional, Hassanein, Mahmoud, additional, Perrone, Sergio V., additional, Ghadanfar, Mathieu, additional, Schweizer, Anja, additional, Obergfell, Achim, additional, Dickstein, Kenneth, additional, Filippatos, Gerasimos, additional, Collins, Sean P., additional, and Lam, Carolyn S.P., additional

Published
2022
Full Text
View/download PDF

44. Effects of remote haemodynamic‐guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS‐HF study

Author

Assmus, Birgit, primary, Angermann, Christiane E., additional, Alkhlout, Basil, additional, Asselbergs, Folkert W., additional, Schnupp, Steffen, additional, Brugts, Jasper J., additional, Nordbeck, Peter, additional, Zhou, Qian, additional, Brett, Marie‐Elena, additional, Ginn, Greg, additional, Adamson, Philip B., additional, Böhm, Michael, additional, and Rosenkranz, Stephan, additional

Published
2022
Full Text
View/download PDF

45. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

Author

Biegus, Jan, primary, Voors, Adriaan A, additional, Collins, Sean P, additional, Kosiborod, Mikhail N, additional, Teerlink, John R, additional, Angermann, Christiane E, additional, Tromp, Jasper, additional, Ferreira, Joao Pedro, additional, Nassif, Michael E, additional, Psotka, Mitchell A, additional, Brueckmann, Martina, additional, Salsali, Afshin, additional, Blatchford, Jonathan P, additional, and Ponikowski, Piotr, additional

Published
2022
Full Text
View/download PDF

46. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

Author

Kosiborod, Mikhail N., primary, Angermann, Christiane E., additional, Collins, Sean P., additional, Teerlink, John R., additional, Ponikowski, Piotr, additional, Biegus, Jan, additional, Comin-Colet, Josep, additional, Ferreira, João Pedro, additional, Mentz, Robert J., additional, Nassif, Michael E., additional, Psotka, Mitchell A., additional, Tromp, Jasper, additional, Brueckmann, Martina, additional, Blatchford, Jonathan P., additional, Salsali, Afshin, additional, and Voors, Adriaan A., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results